ABSTRACT
Benign prostatic hyperplasia (BPH) occurs histologically in approximately 75% of men over 70 years of age and men have a lifetime risk of 10-30% of having a prostatectomy. The introduction of specific medication for patients with lower urinary tract symptoms consistent with bladder outlet obstruction has changed the approach to treatment and management of patients with BPH. The prostate is located at the base of the bladder and the benign enlargement of the central and transitional zones which surround the urethra cause obstruction. The peripheral zone (which harbours 70% of prostatic carcinomas) is compressed as the prostate enlarges. The reasons for enlargement are currently unknown.
